OCCUPATIONAL AND ENVIRONMENTAL HEALTH AND SAFETY

Fact Sheet

THE UNIVERSITY OF UTAH

Zika Virus

The following provides information on the use and containment of Zika virus (ZIKV). Investigators should use these guidelines as part of their risk assessment when planning experiments with these viruses and preparing applications to the Institutional Biosafety Committee (IBC). Note the listed containment levels are the minimum that should be employed with these vectors: some experiments, such as the expression of toxins or oncogenes, may require higher levels of containment. The appropriateness of the containment should be considered as part of the investigator's risk assessment and will be reviewed by the IBC.

NIH Risk Group	To be determined:
	CDC recommends BSL2 containment in the current version of
	the BMBL (5 th edition) but guidelines were published before the
	current epidemic and association with human disease. This
	recommendation for the arbovirus group was based on a) no overt
	laboratory-associated infections are reported, b) infections
	resulted from exposures other than by infectious aerosols, or c) if
	disease from aerosol exposure is documented, it is uncommon.
	Zika virus (ZIKV) is a single-stranded RNA virus of the
	Flaviviridae family, genus Flavivirus, Spondweni group. There
	are two ZIKV lineages: the African lineage and the Asian lineage,
	which has recently emerged in the Pacific and the Americas.
Biocontainment Level	BSL-2 enhanced (BSL2+):
	Biosafety containment requirements: BSL2+ means BSL2
	containment with BSL3 practices and or PPE. Lab specific
	procedures (SOPs) will outline specific containment and practices
	and PPE.
	ABSL2 enhanced (ABSL-2+) for animal work: ABSL2+ means
	ABSL2 containment with BSL3 practices and or PPE.

	Some procedures, large quantities and/or high concentrations may require additional BSL-3 precautions, such as respiratory protection, based on the risk assessment of the proposed work.
Minimum PPE requirements	The following personal protective equipment (PPE) will be
	required when working in the BSL-2+ laboratory:
	Rear closing, fluid resistant disposable or onsite-laundered lab
	coat: if sleeve cuffs are not tight, disposable sleeve covers are
	required
	Gloves (2 pairs)
	Safety glasses or face shield.
	All procedures that may produce aerosols, or involve high
	concentrations or large volumes should be conducted in a
	biological safety cabinet (BSC). The use of needles, syringes, and
	other sharp objects should be strictly limited. Additional
	precautions should be considered with work involving animals or
	large scale activities.
Infectious to	Yes
Humans/Animals	
Route of Transmission	Through Mosquito Bites:
	• Zika virus is transmitted to people primarily through the bite
	of an infected Aedes species mosquito (Ae. Aegypti and Ae.
	albopictus). These are the same mosquitoes that spread
	dengue and chikungunya viruses.
	• These mosquitoes typically lay eggs in and near standing
	water in things like buckets, bowls, animal dishes, flower
	pots and vases. They prefer to bite people, and live
	indoors and outdoors near people.
	• Mosquitoes that spread chikungunya, dengue, and Zika
	are aggressive daytime biters, but they can also bite at
	night.
	• Mosquitoes become infected when they feed on a person
	already infected with the virus. Infected mosquitoes can
	then spread the virus to other people through bites.
	From mother to child
	• A pregnant woman can pass Zika virus to her fetus during
	pregnancy. Zika is a cause of microcephaly and other severe
	fetal brain defects.

	 A pregnant woman already infected with Zika virus can pass the virus to her fetus during the pregnancy or around the time of birth. To date, there are no reports of infants getting Zika virus through breastfeeding.
	 <u>Through sexual contact</u> Zika virus can be spread through sexual transmission. In known cases of male to female sexual transmission, the men developed Zika virus symptoms. From these cases, we know the virus can be spread when the man has symptoms, before symptoms start and after symptoms resolve. The virus is present in semen longer than in blood. A suspected case of female to male sexual transmission was reported on July 15, 2016.
	 <u>Through blood transfusion</u> As of February, 1, 2016, there have not been any confirmed blood transfusion transmission cases in the United States. There have been multiple reports of blood transfusion transmission cases in Brazil. These reports are currently being investigated. During the French Polynesian outbreak, 2.8% of blood donors tested positive for Zika and in previous outbreaks, the virus has been found in blood donors.
	Other Routes There may be other routes of transmission. There is a report of a patient with a high titer of ZIKV passing it to a caregiver and the route of transmission has not been established. Studies have shown that the virus can persist in blood for at least
	two weeks, saliva for up to 2 months and semen for up to 6 months.
Laboratory Hazards	 Prior to the current outbreak, there were four reports of laboratory acquired Zika virus infections, although the route of transmission was not clearly established in all cases. As of June 15, 2016, there has been one reported case of laboratory-acquired Zika virus disease in the United States.
	Laboratory risks include parenteral inoculation, but may also include direct contact with broken skin and mucous membranes

	of the eye, nose and mouth, bites from infected laboratory animals and ingestion.
Medical Surveillance and At- Risk Populations	Prior to working with ZIKV all personnel must receive training on the risks associated with this virus, including signs and symptoms of exposure, populations at increased risk, laboratory standard operating procedures, personal protective equipment and biocontainment, and spill and disinfection procedures. In addition, all personnel must undergo medical counseling with the Department of Occupational Medicine. Please discuss any concerns related to working with ZIKV with the Occupational Medicine Physician. In particular women who are pregnant, may become pregnant, and individuals who are immunocompromised are encouraged to discuss the risks associated with ZIKV infection with a physician.
Symptoms	About 1 in 5 people infected with ZIKV become ill. The most common symptoms of Zika are fever, rash, joint pain, or conjunctivitis (red eyes). Other common symptoms include muscle pain and headache. The illness is usually mild with symptoms lasting for several days to a week. The incubation period (the time from exposure to symptoms) for Zika virus disease is not known, but is likely to be a few days to a week.
	ZIKV infection in pregnancy causes microcephaly of the fetus, as well as other severe fetal brain defects. In addition, ZIKV infection of the fetus may result in deformed limbs, eye defects and hearing loss.Once a person has been infected, he or she is likely to be protected from future infections.
	ZIKV has also been linked to Guillan-Barre syndrome (GBS) and individuals who are affected by an autoimmune disorder and/or are immunosuppressed/immunocompromised may be particularly at risk. GBS symptoms include weakness of the arms and legs that is usually the same on both sides of the body. In some cases, the muscles of the face that control eye movement or swallowing may also become weak. In the most serious cases, this muscle

weakness can affect breathing, and people sometimes need	a
breathing tube to help them breathe.	
ZIKV infection has also been associated with severe	
thrombocytopenia, which is a condition where a patient has	
blood platelet count. Platelets (thrombocytes) are colorless	
cells that help blood clot. Platelets stop bleeding by clumpin	ng and
forming plugs in blood vessel injuries. Typically	
thrombocytopenia may be mild and cause few signs or sym	-
but in severe cases the number of platelets may be so low the	nat
dangerous internal bleeding occurs.	
ZIKV infection has been associated with arthrogryposis, or	
crooked joints, caused by faulty muscles - some too tight or	
contracted and some too flaccid - that have pulled and held	the
baby's growing body in unnatural positions. Babies with	
suspected ZIKV infection have been born with such hip, kn	ee,
ankle, elbow, wrist and/or finger joint problems.	
ZIKV infection of immunocompromised adult mice have	
demonstrated the ability of ZIKV to enter the adult brain an	ld
cause neuropathology.	
Diagnosis Visit the Occupational health clinic if you have been exposed	ed to
ZIKV	
A blood or urine test can confirm a Zika infection.	
Treatment/Prophylaxis There is no vaccine to prevent or medicine to treat Zika viru	18.
1. Treat the symptoms:	
2. Get plenty of rest.	
3. Drink fluids to prevent dehydration.	
4. Take medicine such as acetaminophen or paracetam	ol to
reduce fever and pain.	
5. Take anti-histamines for pruritic rash.	
6. If you are taking medicine for another medical cond	ition,
talk to your doctor or other healthcare provider befo	ore
taking additional medication.	
7. To help prevent transmission to partners via sexual	
	5
contact, abstain from sexual activity or use condoms	
contact, abstain from sexual activity or use condoms during sexual activity during and following infection	n.

	test method against Zika virus. However, as an enveloped virus
	 test method against Zika virus. However, as an enveloped virus, products with proven efficacy against non-enveloped viruses, including other flaviviruses, have been reported to be effective: Sodium hypochlorite (0.5%: use fresh 1:10 dilution of bleach) 70% Ethanol 2% glutaraldehyde
	Inactivation Inactivated by heat and low pH.
	The survival outside of the host is unknown
Exposure Procedures	 Immediately wash affected areas with soap and water, or if exposure to eyes or mucous membranes occurred, immediately flush affected area with water for 10-15 minutes. See exposure procedures for further information.
	 Notify lab supervisor or Principal Investigator of the exposure.
	3. Go directly to the Occupational Medicine Clinic at the Redwood Health Center for medical evaluation and follow- up; contact information is below. After 5pm you will be seen by an Urgent Care Physician. After 8pm, or if the injury is serious/life threatening, go to the University of Utah Hospital Emergency Department or call an ambulance (911).
	 Ensure that the physician is aware that you were exposed or potentially exposed to ZIKV.
	5. Upon returning to work, fill out the Employers First Report of Injury E1 Form. This form can be downloaded from the human resources website under "Forms."
	6. Notify Occupational and Environmental Health and Safety of the exposure (801-581-6590).
	 Follow up with the physician at Occupational Medicine, as requested.

Redwood Health Center

Occupational Medicine Clinic 1525 West 2100 South Salt Lake City, UT 84119 Phone: (801) 213-9777 Hours: M-F 8:00AM – 5:00PM

After Hours

Redwood Urgent Care

1525 West 2100 South Salt Lake City, UT 84119 M-F 5:00PM – 8:00PM Sat.-Sun.: 9:00AM – 8:00PM (801) 213-9700

After 8 PM

Emergency Department at University Hospital (main floor northeast side of the hospital) 50 N. Medical Drive Salt Lake city, UT 84132 (801) 581-2292

Sources:

Center for Disease Control and Prevention (CDC): <u>http://www.cdc.gov/zika/index.html</u> Emory University: http://www.ehso.emory.edu/content-guidelines/BARS-Zika-Virus.pdf